PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 75.78

Change

+1.15 (+1.54)%

Market Cap

N/A

Volume

0.20M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-1.91 (-1.15%)

USD 74.37B
HLN Haleon plc

-0.09 (-0.99%)

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A..

+0.05 (+0.38%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd..

-0.05 (-0.33%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.13 (+1.68%)

USD 3.68B
BHC Bausch Health Companies Inc

+0.08 (+1.08%)

USD 2.91B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

+0.03 (+6.15%)

USD 1.96M

ETFs Containing PBH

NDIA Global X Funds 3.47 % 0.00 %

+0.04 (+0.52%)

USD 0.02B
EMC Global X Funds 2.40 % 0.00 %

+0.13 (+0.52%)

USD 0.10B
XST:CA iShares S&P/TSX Capped Co.. 0.00 % 0.61 %

-0.87 (0.52%)

CAD 0.27B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.96% 57% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.96% 57% F 17% F
Trailing 12 Months  
Capital Gain 28.33% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.33% 73% C 83% B
Trailing 5 Years  
Capital Gain 80.90% 86% B+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.90% 86% B+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 18.71% 80% B- 79% B-
Dividend Return 18.71% 80% B- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.77% 73% C 53% F
Risk Adjusted Return 90.10% 100% F 92% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike